CHROMagar: Single-step, Chromogenic Testing Media for Colorful Microbial Detection
The Widest Range of Chromogenic Media Available on the Market
CHROMagar ™ supplies the widest range of chromogenic culture media available today
CHROMagar ™ covers applications in clinical bacteriology, industrial microbiology, quality control for food and beverage industries, water testing and environmental monitoring, among others. These media allow for a quicker and simpler detection of key clinical and food-borne pathogens, including Salmonella, Staph aureus, Candida albicans, E.coli O157, Group B Strep, E.coli, Listeria, Vibrio and Pseudomonas.
Research-driven and high-tech, CHROMagar ™ consists of a select team of highly-trained scientists and technicians led by its founder Dr. Rambach. A leader in the innovative field of chromogenic culture media technology, CHROMagar ™ is a commercially successful and growing enterprise with efficient international reach through its worldwide distribution network.
From pioneer research to cutting edge techniques, CHROMagar ™ leads the way in chromogenic media.
CHROMagar™ Microbiology was incorporated in 1993 by inventor, and pioneer in chromogenic media technology, Alain Rambach. Established in the heart of Paris (France), not far from the famous Pasteur Institute where Dr. Rambach began his research career, CHROMagar™ provides innovative chromogenic culture media solutions, designed to improve and simplify traditional culture techniques. CHROMagar™ is at the cutting edge of a diagnostic field that developed out of Dr. Rambach’s pioneering research in the late 1970’s.
30 years’ experience, specialization and know-how.
Innovation and research
Worldwide recognition and an international distribution network
DRG is proud to announce the launch of two new Anti-Müllerian Hormone (AMH) assays: AMH ELISA (EIA-6141) AMH DRG HYBRiD XL® (HYE-5770) Clinical Application: AMH has been identified as a reliable marker of ovarian reserve that can help predict early ovarian...
The growth and further development of the North American market is a key priority for us and the sole focus of the new Sales and Business Development Executive we are looking to recruit.
On April 30th, 2020, an organized study by Radboud University Medical Center in Nijmegen, Netherlands, has completed a final report for the DRG International’s first ever Hepcidin Proficiency Test.